The Clinical Trials Unit Resource (CTUR) component ofthe CDU/UCI^ Cancer Center Partnership will be charged with the overarching goal of enhancing minority participation in clinical research and clinical trials. The accomplishment of this goal will further develop the institutional capacity at CDU in the area of cancer-related clinical trials by leveraging existing clinical research facilities and resources. Specifically, the partnership will enhance the established Clinical Research Center (CRC) at CDU;the clinical trials component ofthe CRC, called the Clinical Center for Research Excellence (CCRE), was developed to enhance CDU's infrastructure for clinical studies and is headed by Dr. Mayer Davidson. The CDU-UCLA partnership will continue to build upon the current infrastructure to enhance the ability to conduct effective clinical studies in cancer heath disparities. The specific objectives of the Resources activities are as follows:
Specific Aim 1 : Enhance the recruitment and retention of racial and ethnic minorities into clinical trials related to cancer at the CRC;
Specific Aim 2 : Provide training and assistance in the design, development, and execution of CDU clinical cancer research studies;
Specific Aim 3 : Communicate and solicit feedback regarding clinical trials with the community via the Outreach Program;
and Specific Aim 4 : Employ external reviewers to assess the quality and strength ofthe clinical results. These reviewers will be engaged at the eariiest onset to provide input in the development of clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143930-05
Application #
8543593
Study Section
Special Emphasis Panel (ZCA1-SRLB-D)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$92,470
Indirect Cost
$31,648
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Boonyaratanakornkit, Viroj; Hamilton, Nalo; Márquez-Garbán, Diana C et al. (2018) Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol 466:51-72
Elshimali, Yahya I; Wu, Yong; Khaddour, Hussein et al. (2018) Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 1:
Gelfand, Robert; Vernet, Dolores; Bruhn, Kevin W et al. (2017) Long-term exposure of MCF-7 breast cancer cells to ethanol stimulates oncogenic features. Int J Oncol 50:49-65
Dong, Yunzhou; Wu, Yong; Cui, Mei-Zhen et al. (2017) Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21. Mediators Inflamm 2017:2754756
Wu, Yanyuan; Sarkissyan, Marianna; Clayton, Sheilah et al. (2017) Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. Cancers (Basel) 9:
Chung, Seyung S; Adekoya, Debbie; Enenmoh, Ikechukwu et al. (2017) Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells. Anticancer Res 37:445-453
Maxwell, Annette E; Crespi, Catherine M; Arce, Anthony A et al. (2017) Exploring the effects of longstanding academic-community partnerships on study outcomes: A case study. Prev Med Rep 8:101-107
Hamilton, Nalo; Austin, David; Márquez-Garbán, Diana et al. (2017) Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci 18:
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394

Showing the most recent 10 out of 52 publications